Galvanize Therapeutics logo

Galvanize Therapeutics

Commercial-stage medtech company pioneering pulsed electric field ablation for oncology and chronic disease.

ShareLink copied

The record

Vertical
Medical Devices
Sub-segment
Pulsed electric field ablation
Product type
Medical device
Stage
Series D
Headquarters
Redwood City, CA, United States
Region
North America

What they do

Galvanize Therapeutics is a commercial-stage medical technology company pioneering pulsed electric field (PEF) ablation technologies for oncology and chronic disease. It is commercializing the Aliya PEF platform in the United States and advancing a pipeline that includes RheOx therapy for chronic bronchitis. On November 16, 2026, the company announced an oversubscribed $130 million Series D led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell LP joining as new investors. Proceeds will support continued commercial expansion of Aliya, clinical evidence generation, advancement of RheOx therapy for chronic bronchitis, and development of next-generation PEF products and platforms.

Leadership & founders

  • Doug Godshall

    Chairman and Chief Executive Officer

  • Garheng Kong, MD, PhD

    Board member (Founder and Managing Partner, HealthQuest Capital), joining in connection with the Series D

Investors

History and progression

How Galvanize Therapeutics got here, step by step.

  1. 16 November 2026

    $130 million Series D

    Galvanize announced an oversubscribed $130 million Series D led by HealthQuest Capital, with Olympus Innovation Ventures and Braidwell LP as new investors and participation from existing investors including Sofinnova Partners, Norwest and T. Rowe Price Associates, Inc.

Pipeline and programmes

RheOx therapy
Chronic bronchitis

Key products

Aliya PEF System
A pulsed electric field ablation system for soft tissue.
Aliya EX
The next-generation generator for the Aliya PEF System. The company said it has received FDA clearance and commercially launched Aliya EX.

Recent news

  1. 16 November 2026

    Galvanize Therapeutics Raises $130 Million in Oversubscribed Series D Financing
  2. 16 November 2026

    $130 million Series D round
  3. 18 November 2026

    Doug Godshall, Chairman and CEO

Your daily HealthTech Signal

No hype. Just signal.

Get the latest HealthTech news, understand why it matters, and see where the industry is headed.

5-minute read Delivered daily Unsubscribe anytime

Read by teams at companies like:

Mayo Clinic logoMayo ClinicCleveland Clinic logoCleveland ClinicJohns Hopkins logoJohns HopkinsKaiser Permanente logoKaiser PermanenteEpic logoEpicPhilips logoPhilipsMedtronic logoMedtronicGE HealthCare logoGE HealthCare

Is this your company? Get a Verified profile